CIK 0001674416 · Large accelerated filer
CRISPR Therapeutics AG
Sign in to watch- Ticker
- CRSP
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- Switzerland
- Entity type
- operating
- EIN
- 473173478
- Phone
- 6173154600
- Business address
- BAARERSTRASSE 14, ZUG, Switzerland
- Former names
- CRISPR Therapeutics AG
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $4,881,673
- in 7 filings, $1.5M under 10b5-1 plans
Net −$4,881,673. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-11-04 | Sakhamuri Sivakesava Chief Technical Officer | Grant or award · Stock Option (Right to Buy) | +90,000 | 90,000 | ||
| 2026-11-04 | Sakhamuri Sivakesava Chief Technical Officer | Grant or award · Restricted Stock Units | +40,000 | 40,000 | ||
| 2026-10-26 | Silver Andrew Jacob Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +18,000 | 18,000 | ||
| 2026-10-26 | Silver Andrew Jacob Chief Financial Officer | Grant or award · Restricted Stock Units | +9,000 | 9,000 | ||
| 2026-10-26 | KASINGER JAMES R. General Counsel and Secretary | Grant or award · Stock Option (Right to Buy) | +18,000 | 18,000 | ||
| 2026-10-26 | KASINGER JAMES R. General Counsel and Secretary | Grant or award · Restricted Stock Units | +9,000 | 9,000 | ||
| 2026-10-26 | Kulkarni Samarth Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +57,500 | 57,500 | ||
| 2026-10-26 | Kulkarni Samarth Chief Executive Officer | Grant or award · Restricted Stock Units | +28,750 | 28,750 | ||
| 2026-10-26 | Patel Naimish Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +24,000 | 24,000 | ||
| 2026-10-26 | Patel Naimish Chief Medical Officer | Grant or award · Restricted Stock Units | +12,000 | 12,000 | ||
| 2026-10-19 | Silver Andrew Jacob Chief Financial Officer | Grant or award · Restricted Stock Units | +25,000 | 25,000 | ||
| 2026-10-19 | Kulkarni Samarth Chief Executive Officer | Sale | −47,837 | $49.78 | $2.4M | 311,899 |
| 2026-10-16 | Kulkarni Samarth Chief Executive Officer | Option exercise | +100,000 | 359,736 | ||
| 2026-10-16 | Kulkarni Samarth Chief Executive Officer | Option exercise · Restricted Stock Units | −100,000 | 200,000 | ||
| 2026-10-14 | George Simeon Director | Option exercise 10b5-1 | +30,000 | $14.00 | $420K | 30,000 |
| 2026-10-14 | George Simeon Director | Sale 10b5-1 | −14,514 | $49.63 | $720K | 15,486 |
| 2026-10-14 | George Simeon Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −30,000 | 0 | ||
| 2026-10-14 | KASINGER JAMES R. General Counsel and Secretary | Sale | −1,040 | $49.26 | $51K | 95,857 |
| 2026-10-14 | Kulkarni Samarth Chief Executive Officer | Sale | −4,098 | $49.26 | $202K | 259,736 |
| 2026-10-13 | KASINGER JAMES R. General Counsel and Secretary | Option exercise | +2,113 | 96,897 |
Page 1 of 46 · 910 trades